Almirall, member of CataloniaBio & HealthTech, continues its inorganic growth strategy to enhance its portfolio of dermatological products. The pharmaceutical company of the Gallardo family has reached an agreement with the Belgian firm Etherna to use its RNA technology and develop products for serious skin diseases, including non-melanoma skin cancer. The agreement includes an initial payment, the amount of which has not been disclosed but sources close to the operation assure that it is not significant, and a potential payment of over 300 million euros if a product reaches the market.
As is often the case in most agreements between pharmaceutical companies for potential drugs, the total amount is divided into achieving milestones. In the current case between Almirall and Etherna, payments will be made as development milestones (overcoming clinical trials) and commercial milestones (sales completion) are achieved, as well as for the payment of royalties staggered according to the volume of income.
"At Almirall, we are constantly searching for new solutions for patients suffering from skin diseases. This strategic alliance with Etherna is another step in this direction, as it allows us to strengthen our pipeline with assets based on mRNA," explain from the Catalan firm. In fact, this is the third operation since the company announced a capital increase of 200 million euros last June. Previously, in addition to deepening in the main business (medical dermatology), the company has also acquired products for Alzheimer's.
Comments